Yin 2018.

Study characteristics
Methods	Study design: prospective, RCT Duration of study: June 2015 to May 2017 Duration of follow‐up: until day 90 after randomisation
Participants	Setting: single‐centre Country: China Critically ill patients with septic shock and AKI; ≥ 18 years Number: intervention group (33); control group (30) Mean age ± SD (years): intervention group (58.6 ± 18.53); control group (63.20 ± 9.66) Sex (M/F): intervention group (23/10); control group (19/11) Exclusion criteria: malignant tumour; hypoxic ischaemic encephalopathy; hepatic disease; CKD; blood disease; contraindications to CKRT treatment; breastfeeding or pregnant
Interventions	KRT modality CKRT Intervention group Early‐strategy group: patient with AKI RIFLE‐F stage CKRT started within 12 hours after randomisation Control group Standard‐strategy group: patient with AKI RIFLE‐F stage CKRT started ≥ 48 hours after randomisation
Outcomes	Primary outcome Death at days 28, 60 and 90 Secondary outcome Survival Mechanical ventilation time ICU stay Hospital stay
Notes	Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement Quote: "All patients were divided randomly into two groups"
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Insufficient information to permit judgement (for kidney recovery was unclear risk but for death was low risk)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The outcome measurement is not likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete outcome data were reported
Selective reporting (reporting bias)	Low risk	The study reported death, ICU and hospital stay
Other bias	Unclear risk	Insufficient information to permit judgement

AIDS: acquired immune deficiency syndrome; AKI: acute kidney injury; AKIN: Acute Kidney Injury Network; Ang2: angiopoietin‐2; BUN: blood urea nitrogen; CKD: chronic kidney disease; CrCl: creatinine clearance; CKRT: continuous kidney replacement therapy; CVVH: continuous venovenous haemofiltration; CVVHDF: continuous venovenous haemodiafiltration; FST: furosemide stress test; HD: haemodialysis; HF ‐ haemofiltration; (e)GFR: (estimated) glomerular filtration rate; GN: glomerulonephritis; HF: haemofiltration; ICU: intensive care unit; IHD: intermittent haemodialysis; KDIGO: Kidney Disease: Improving Global Outcomes; KRT: kidney replacement therapy; M/F: male/female; NGAL: plasma neutrophil gelatinase‐associated lipocalin; NT‐proBNP: N‐terminal‐pro hormone brain natriuretic peptide; PIKRT: prolonged intermittent kidney replacement therapy; QoL: quality of life; RCT: randomised controlled trial; RIFLE: Risk Injury Failure Loss ESKD; SCr: serum creatinine; SD: standard deviation; SOFA: Sequential Organ Failure Assessment; UF: ultrafiltration